Search
Urogen Pharma Ltd
URGNAdd to Watchlist
37.940USD
+1.140+3.10%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.85BMarket Cap
LossP/E TTM
More Details of Urogen Pharma Ltd Company
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd Info
Ticker SymbolURGN
Company nameUrogen Pharma Ltd
IPO dateMay 04, 2017
CEOBarrett (Elizabeth A)
Number of employees235
Security typeOrdinary Share
Fiscal year-endMay 04
Address9 Ha'ta'asiya St
CityRA'ANANA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code4365007
Phone97297707601
Websitehttps://www.urogen.com/
Ticker SymbolURGN
IPO dateMay 04, 2017
CEOBarrett (Elizabeth A)
Company Executives of Urogen Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Urogen Pharma Ltd?
The top five shareholders of Urogen Pharma Ltd are: Dr. Arie S. Belldegrun, M.D.
How many institutions hold shares of Urogen Pharma Ltd (URGN)?
As of 2026Q1, 349 institutions hold shares of Urogen Pharma Ltd, with a combined market value of approximately 46.29M, accounting for 95.00% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -15691017.00.
What is the biggest source of revenue for Urogen Pharma Ltd?
In 2026Q1, the Jelmyto business generated the highest revenue for Urogen Pharma Ltd, amounting to 93.99M and accounting for 85.61% of total revenue.